Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria
Open Access
- 11 April 2024
- journal article
- research article
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 37 (3) , 266-269
Abstract
Introduction. Mycobacterium avium complex (MAC) and Mycobacterium abscessus are a group of nontuberculous mycobacteria (NTM) that have been described as human pathogens. Their ability to develop biofilms in tissues and medical devices is one of the most important pathogenicity factors, with important implications in diagnosis and treatment. Macrolides are usually considered one of the bases of this treatment. Methods. Here we have studied the biofilm prevention concentration (BPC) of 16 strains (n=16) with clarithromycin to avoid the biofilm development by these NTM. Results. In this study, all M. abscessus strains have similar BPC, while MAC strains showed different values. For MAC the concentrations ranged between 1-16 mg/L, while for M. abscessus the concentration was 32 mg/L for all strains except one that was 64 mg/L. Conclusions. These results open the possibility of using macrolides for the prevention of biofilm development in patients with a risk of developing NTM disease.Keywords
This publication has 16 references indexed in Scilit:
- Antibiofilm effect of antimicrobials used in the therapy of mycobacteriosisMicrobial Pathogenesis, 2016
- Chronic pulmonary disease withMycobacterium abscessuscomplex is a biofilm infectionEuropean Respiratory Journal, 2015
- Adherence and biofilm formation of Mycobacterium avium ,Mycobacterium intracellulare and Mycobacterium abscessus to household plumbing materialsJournal of Applied Microbiology, 2013
- Absence of Mycobacterium intracellulare and Presence of Mycobacterium chimaera in Household Water and Biofilm Samples of Patients in the United States with Mycobacterium avium Complex Respiratory DiseaseJournal of Clinical Microbiology, 2013
- In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patientsInternational Journal of Antimicrobial Agents, 2012
- Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessusInternational Journal of Systematic and Evolutionary Microbiology, 2011
- Biofilm development by clinical strains of non-pigmented rapidly growing mycobacteriaClinical Microbiology and Infection, 2009
- A Subinhibitory Concentration of Clarithromycin Inhibits Mycobacterium avium Biofilm FormationAntimicrobial Agents and Chemotherapy, 2004
- Characterization of biofilm formation by clinical isolates of Mycobacterium aviumJournal of Medical Microbiology, 2003
- A Randomized Trial of Clarithromycin as Prophylaxis against DisseminatedMycobacterium aviumComplex Infection in Patients with Advanced Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1996